Primary mediastinal large B-cell lymphoma

6 trials 2 recruiting MedDRA PT
6 Registered trials
2 Recruiting
5 Unique sponsors
2 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
CAR-T cell therapy 1 substance
BTK inhibitor 1 substance
Phase III: 2 Phase I: 3 Phase I (First in Human): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

2 trials
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-508343-48-00 7 countries 2019 n=128
    Ended
  • University Of Saarland Academic
    ACALABRUTINIB
    2022-501187-18-00 2 countries 2023 n=360
    Recruiting

Phase I

3 trials
  • Incyte Corp. Commercial
    IMP not specified
    2022-501505-13-00 4 countries 2023 n=140
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2022-502390-41-00 4 countries 2024 n=35
    Ended
  • Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic
    IMP not specified
    2023-507213-97-00 1 country 2024 n=52
    Recruiting

Phase I (First in Human)

1 trial
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2023-507062-34-00 5 countries 2020 n=142
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 2 Phase III, Phase I (First in Human) 0
Incyte Corp. Commercial 1 Phase I 0
Seagen Inc. Commercial 1 Phase I 0
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic 1 Phase I 1
University Of Saarland Academic 1 Phase III 1
New trials by year
2019
1
2020
1
2023
2
2024
2
← All indication landscapes